This antibody detects LRRFIP1 at C-term. LRRFIP1 antibody is predicted to not cross-react with other LRRFIP family members. Three isoforms of LRRFIP1 are known to exist, this antibody will only recognize the two longer isoforms.
Kreuzreaktivität (Details)
Species reactivity (tested):Human
Aufreinigung
Affinity chromatography purified via peptide column
Immunogen
19 amino acid peptide near the carboxy terminus of human LRRFIP1
Optimal working dilution should be determined by the investigator.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Buffer
PBS containing 0.02 % sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store at 2 - 8 °C for up to three months or (in aliquots) at -20 °C for longer.
Target
LRRFIP1
(Leucine Rich Repeat (In FLII) Interacting Protein 1 (LRRFIP1))
Andere Bezeichnung
LRRFIP1
Hintergrund
LRRFIP1, also known as GC-binding factor 2 (GCF2), is a 738 amino acid transcriptional repressor that mainly plays a cytoskeletal role. It is primarily localized in the cytoplasm and preferentially binds to GC-rich dsDNA, but will also bind directly to dsRNA as well. The RNA binding domain encompasses a lysine-rich motif. LRRFIP1 interacts with the mammalian Flightless I (Fli-I) and is a key component in the cytoskeletal regulation of platelet function. LRRFIP1 and the related protein LRRFIP2 may modulate canonical WNT signaling and mediate the IRF3-induced production of type I interferon via a B-catenin-dependent pathway.Synonyms: GC-binding factor 2, GCF2, LRR FLII-interacting protein 1, Leucine-rich repeat flightless-interacting protein 1, TAR RNA-interacting protein, TRIP